MCID: DXR001
MIFTS: 30

Doxorubicin Induced Cardiomyopathy malady

Rare diseases, Cardiovascular diseases categories

Aliases & Classifications for Doxorubicin Induced Cardiomyopathy

About this section

Aliases & Descriptions for Doxorubicin Induced Cardiomyopathy:

Name: Doxorubicin Induced Cardiomyopathy 45


Classifications:



Summaries for Doxorubicin Induced Cardiomyopathy

About this section
MalaCards based summary: Doxorubicin Induced Cardiomyopathy is related to cardiomyopathy and sarcoma. An important gene associated with Doxorubicin Induced Cardiomyopathy is GATA4 (GATA Binding Protein 4), and among its related pathways are Physiological and Pathological Hypertrophy of the Heart and G-protein signaling_K-RAS regulation pathway. Affiliated tissues include heart, bone and bone marrow, and related mouse phenotypes are no phenotypic analysis and respiratory system.

Related Diseases for Doxorubicin Induced Cardiomyopathy

About this section

Graphical network of diseases related to Doxorubicin Induced Cardiomyopathy:



Diseases related to doxorubicin induced cardiomyopathy

Symptoms for Doxorubicin Induced Cardiomyopathy

About this section

Drugs & Therapeutics for Doxorubicin Induced Cardiomyopathy

About this section

Drugs for Doxorubicin Induced Cardiomyopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Doxorubicinapproved, investigationalPhase 2, Phase 3152523214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
2
DoxilApproved June 1999Phase 2, Phase 3152531703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin

Interventional clinical trials:

idNameStatusNCT IDPhase
1Correlation Between Genetic Variants and Long-term Cardiac Effects Induced by Doxorubicin in Breast Cancer PatientsRecruitingNCT02078388Phase 2, Phase 3
299mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast CancerNot yet recruitingNCT02677714Phase 2

Search NIH Clinical Center for Doxorubicin Induced Cardiomyopathy

Genetic Tests for Doxorubicin Induced Cardiomyopathy

About this section

Anatomical Context for Doxorubicin Induced Cardiomyopathy

About this section

MalaCards organs/tissues related to Doxorubicin Induced Cardiomyopathy:

33
Heart, Bone, Bone marrow, Myeloid, Testes, Pituitary, Breast

Animal Models for Doxorubicin Induced Cardiomyopathy or affiliated genes

About this section

MGI Mouse Phenotypes related to Doxorubicin Induced Cardiomyopathy:

38 (show all 19)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00030128.5CNR1, EGFR, EPOR, GATA4, HGF, MET
2MP:00053888.5EGFR, EPOR, GATA4, MAPK14, MET
3MP:00053818.3CNR1, ECE1, EGFR, EPHB2, GATA4, MET
4MP:00053708.3EGFR, EPOR, GATA4, HGF, MAPK14, MET
5MP:00053698.1DES, ECE1, EGFR, GATA4, MAPK14, MET
6MP:00028737.7CNR1, ECE1, EGFR, EPOR, GATA4, MAPK14
7MP:00053797.7ECE1, EGFR, EPHB2, GATA4, MAPK14, MET
8MP:00053807.7ECE1, EGFR, EPOR, GATA4, HGF, MAPK14
9MP:00053847.5CNR1, EGFR, EPHB2, EPOR, GATA4, HGF
10MP:00053787.4CNR1, EGFR, EPHB2, EPOR, GATA4, HGF
11MP:00053857.4DES, ECE1, EGFR, EPOR, GATA4, HGF
12MP:00036317.1CNR1, ECE1, EGFR, EPHB2, EPOR, GATA4
13MP:00053977.1CSF3, ECE1, EGFR, EPOR, GATA4, HGF
14MP:00053767.1CNR1, DES, ECE1, EGFR, EPOR, GATA4
15MP:00107686.6CNR1, DES, ECE1, EGFR, EPHB2, EPOR

Publications for Doxorubicin Induced Cardiomyopathy

About this section

Articles related to Doxorubicin Induced Cardiomyopathy:

(show top 50)    (show all 125)
idTitleAuthorsYear
1
Protective effects of endothelin receptor A and B inhibitors against doxorubicin-induced cardiomyopathy. (25660617)
2015
2
Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. (25569804)
2015
3
A metabolomic study of rats with doxorubicin-induced cardiomyopathy and Shengmai injection treatment. (25938766)
2015
4
Potent Paracrine Effects of human induced Pluripotent Stem Cell-derived Mesenchymal Stem Cells Attenuate Doxorubicin-induced Cardiomyopathy. (26057572)
2015
5
Protective effect of cilostazol against doxorubicin-induced cardiomyopathy in mice. (26191652)
2015
6
Heart rate dynamics in doxorubicin-induced cardiomyopathy. (25798626)
2015
7
Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy. (26511374)
2015
8
Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism. (24486195)
2014
9
Interrelation between Expression of ADAM 10 and MMP 9 and Synthesis of Peroxynitrite in Doxorubicin Induced Cardiomyopathy. (24244825)
2013
10
Manipulation of Cardiac PI3K/Akt Signaling by Apoptosis regulator through modulating IAP expression (ARIA) Regulates Cardiomyocyte Death during the Doxorubicin-induced Cardiomyopathy. (24338479)
2013
11
Antioxidant, lipid lowering, and membrane stabilization effect of sesamol against doxorubicin-induced cardiomyopathy in experimental rats. (24228260)
2013
12
Increased beta2-adrenoceptors in doxorubicin-induced cardiomyopathy in rat. (23741376)
2013
13
Embryonic stem cells improve cardiac function in Doxorubicin-induced cardiomyopathy mediated through multiple mechanisms. (22449713)
2012
14
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. (22465037)
2012
15
Discordant impairment of multidirectional myocardial deformation in rats with Doxorubicin induced cardiomyopathy. (22486544)
2012
16
Inorganic nitrate therapy improves Doxorubicin-induced cardiomyopathy a new window for an affordable cardiovascular therapy for everyone? (21596235)
2011
17
Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation ofA mitochondrial function. (21094500)
2011
18
Potential biomarkers in mouse myocardium of doxorubicin-induced cardiomyopathy: a metabonomic method and its application. (22110719)
2011
19
Thrombopoietin protects against doxorubicin-induced cardiomyopathy, improves cardiac function, and reversely alters specific signalling networks. (21330293)
2011
20
Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy. (21946105)
2011
21
S-diclofenac protects against doxorubicin-induced cardiomyopathy in mice via ameliorating cardiac gap junction remodeling. (22039489)
2011
22
Diclofenac sodium, a nonselective nonsteroidal anti-inflammatory drug aggravates doxorubicin-induced cardiomyopathy in rats. (19920767)
2010
23
Involvement of advanced glycation end-products, pentosidine and N(epsilon)-(carboxymethyl)lysine, in doxorubicin-induced cardiomyopathy in rats. (20004697)
2010
24
Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. (20543097)
2010
25
How to protect doxorubicin-induced cardiomyopathy in male albino rats? (20051877)
2010
26
CO liberated from a carbon monoxide-releasing molecule exerts a positive inotropic effect in doxorubicin-induced cardiomyopathy. (19935076)
2010
27
CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. (19942623)
2010
28
Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. (19010377)
2009
29
Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model. (18379782)
2009
30
Treatment with an adenoviral vector encoding hepatocyte growth factor mitigates established cardiac dysfunction in doxorubicin-induced cardiomyopathy. (18083897)
2008
31
Granulocyte colony-stimulating factor improves left ventricular function of doxorubicin-induced cardiomyopathy. (17334414)
2007
32
Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. (16449733)
2006
33
Overexpression of Nd1, a novel Kelch family protein, in the heart of transgenic mice protects against doxorubicin-induced cardiomyopathy. (16952015)
2006
34
Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy. (16039240)
2005
35
Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. (16364871)
2005
36
Anti-oxidants and apoptosis: attenuation of doxorubicin induced cardiomyopathy by carvedilol. (15380672)
2004
37
Mechanical unloading improves intracellular Ca2+ regulation in rats with doxorubicin-induced cardiomyopathy. (15582323)
2004
38
Molecular biology of doxorubicin-induced cardiomyopathy. (19644577)
2002
39
Doxorubicin-induced cardiomyopathy during pregnancy: three case reports of anesthetic management for cesarean and vaginal delivery in two kyphoscoliotic patients. (12151947)
2002
40
Doxorubicin-induced cardiomyopathy. (10910374)
2000
41
Evaluation of cardiac adrenergic neuronal damage in rats with doxorubicin-induced cardiomyopathy using iodine-131 MIBG autoradiography and PGP 9.5 immunohistochemistry. (10901455)
2000
42
Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. (10503942)
1999
43
Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. (9848575)
1998
44
Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. (9038198)
1997
45
Contractile failure in chronic doxorubicin-induced cardiomyopathy. (9344758)
1997
46
Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin. (7831179)
1994
47
Etiology of sarcoplasmic reticulum calcium release channel lesions in doxorubicin-induced cardiomyopathy. (1314436)
1992
48
Case presentation of doxorubicin-induced cardiomyopathy: a short- and long-term side effect of pediatric cancer treatment. (1675089)
1991
49
Activity of receptors coupled to guanine nucleotide binding regulatory protein in doxorubicin induced cardiomyopathy. (1660348)
1991
50
Diminishment of respiratory sinus arrhythmia foreshadows doxorubicin-induced cardiomyopathy. (1860214)
1991

Variations for Doxorubicin Induced Cardiomyopathy

About this section

Expression for genes affiliated with Doxorubicin Induced Cardiomyopathy

About this section
Search GEO for disease gene expression data for Doxorubicin Induced Cardiomyopathy.

Pathways for genes affiliated with Doxorubicin Induced Cardiomyopathy

About this section

Pathways related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 24)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.7GATA4, MAPK14
29.6EGFR, EPOR
39.5HGF, MET
49.4EGFR, MET
59.1EGFR, HGF, MET
69.1EGFR, HGF, MET
79.1EGFR, HGF, MET
89.1EGFR, HGF, MET
99.0EGFR, EPHB2, MET
10
Show member pathways
8.8EGFR, EPOR, GATA4, MAPK14
118.7CSF3, HGF, MET
128.6EGFR, HGF, MAPK14, MET
13
Show member pathways
8.3EGFR, EPHB2, EPOR, HGF, MET
14
Show member pathways
8.2CNR1, EGFR, HGF, MAPK14, MET
15
Show member pathways
8.2EGFR, EPHB2, HGF, MAPK14, MET
16
Show member pathways
8.1EGFR, EPHB2, EPOR, MAPK14, MET
177.8CSF3, EGFR, EPOR, HGF, MET
18
Show member pathways
7.8EGFR, EPHB2, EPOR, HGF, MAPK14, MET
19
Show member pathways
7.8EGFR, EPHB2, EPOR, HGF, MAPK14, MET
20
Show member pathways
7.8EGFR, EPHB2, EPOR, HGF, MAPK14, MET
21
Show member pathways
7.5EGFR, EPHB2, EPOR, GATA4, HGF, MAPK14
22
Show member pathways
6.9CSF3, EGFR, EPHB2, EPOR, HGF, MAPK14
23
Show member pathways
6.6CSF3, DES, EGFR, EPHB2, EPOR, HGF
24
Show member pathways
6.4CSF3, ECE1, EGFR, EPHB2, EPOR, HGF

GO Terms for genes affiliated with Doxorubicin Induced Cardiomyopathy

About this section

Biological processes related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1axonal fasciculationGO:000741310.2CNR1, EPHB2
2myoblast proliferationGO:005145010.2HGF, MET
3regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signalingGO:006066510.2HGF, MET
4negative regulation of hydrogen peroxide-mediated programmed cell deathGO:190129910.2HGF, MET
5hepatocyte growth factor receptor signaling pathwayGO:004801210.1HGF, MET
6positive chemotaxisGO:00509189.9HGF, MET
7negative regulation of autophagyGO:00105079.6GATA4, HGF, MET
8transmembrane receptor protein tyrosine kinase signaling pathwayGO:00071699.3EGFR, EPHB2, MET
9protein autophosphorylationGO:00467779.1EGFR, MAPK14, MET
10peptidyl-tyrosine phosphorylationGO:00181089.0EGFR, EPHB2, MET
11heart developmentGO:00075079.0ECE1, EPOR, GATA4
12activation of MAPK activityGO:00001878.9HGF, MAPK14, MET
13protein phosphorylationGO:00064688.6EGFR, EPHB2, MAPK14, MET
14positive regulation of transcription from RNA polymerase II promoterGO:00459448.0CSF3, EGFR, GATA4, HGF, MET

Molecular functions related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1NFAT protein bindingGO:005152510.3GATA4, MAPK14
2transmembrane receptor protein tyrosine kinase activityGO:00047149.5EGFR, MET
3protein phosphatase bindingGO:00199039.2EGFR, MAPK14, MET
4identical protein bindingGO:00428029.0DES, EGFR, EPOR, HGF
5protein tyrosine kinase activityGO:00047138.9EGFR, EPHB2, MET
6protein kinase activityGO:00046728.5EGFR, EPHB2, MAPK14, MET

Sources for Doxorubicin Induced Cardiomyopathy

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet